|
MITD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.22100140898374E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.81190000173126E-08 |
| Normal-vs-Stage2 |
1.00479957687583E-10 |
| Normal-vs-Stage3 |
1.96930000084805E-08 |
| Normal-vs-Stage4 |
1.85990000067804E-08 |
| Stage1-vs-Stage2 |
5.94159999999233E-05 |
| Stage1-vs-Stage3 |
2.219200E-01 |
| Stage1-vs-Stage4 |
9.176200E-02 |
| Stage2-vs-Stage3 |
5.524400E-03 |
| Stage2-vs-Stage4 |
2.284200E-02 |
| Stage3-vs-Stage4 |
6.489000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.1243994624266E-10 |
| Normal-vs-AfricanAmerican |
8.25690005257229E-09 |
| Normal-vs-Asian |
2.593700E-04 |
| Caucasian-vs-AfricanAmerican |
6.140500E-02 |
| Caucasian-vs-Asian |
6.055800E-01 |
| AfricanAmerican-vs-Asian |
9.899800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.66510000232378E-08 |
| Normal-vs-Female |
1.42679978942795E-10 |
| Male-vs-Female |
8.066600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00650000001146E-06 |
| Normal-vs-Age(41-60Yrs) |
1.22539978164582E-10 |
| Normal-vs-Age(61-80Yrs) |
1.81480053207395E-10 |
| Normal-vs-Age(81-100Yrs) |
3.030700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.054300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.656700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.073400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.515600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.357000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.552200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.985600E-01 |
| Classical-VS-Follicular |
7.207800E-02 |
| Classical-VS-Other |
3.948200E-01 |
| Classical-VS-Normal |
2.2934999999169E-07 |
| Tall-VS-Follicular |
1.447810E-01 |
| Tall-VS-Other |
6.980000E-01 |
| Tall-VS-Normal |
1.902260E-03 |
| Follicular-VS-Other |
2.673200E-01 |
| Follicular-VS-Normal |
1.96839999966336E-07 |
| Other-VS-Normal |
1.333380E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.67790020661118E-10 |
| Normal-vs-N1 |
1.85069999999454E-05 |
| N0-vs-N1 |
1.050850E-01 |
|
|
